Ureter Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ureter Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra, and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy, and radiation therapy.
The Ureter Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ureter Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 46 molecules, with 42 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ureter Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ureter Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ureter Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akamis Bio LtdAravive Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Oncology Ltd
Bayer AG
BeiGene Ltd
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Coherent Biopharma
Evaxion Biotech A/S
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Gilead Sciences Inc
GlyTherix Ltd
Hangzhou DAC Biotech Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
Icahn School of Medicine at Mount Sinai
IO Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
MedPacto Inc
Merck & Co Inc
Merck KGaA
Minghui Pharmaceutical (Shanghai) Co Ltd
NeoTX Therapeutics Ltd
Peking University
Pfizer Inc
Puretech Health Plc
RemeGen Co Ltd
Seagen Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Miracogen Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Geno-Immune Medical Institute
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ureter Cancer reports